Invesco Pharmaceuticals ETF
PJP
99 hedge funds and large institutions have $107M invested in Invesco Pharmaceuticals ETF in 2017 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 21 increasing their positions, 34 reducing their positions, and 11 closing their positions.
274% more call options, than puts
Call options by funds: $1.72M | Put options by funds: $458K
27% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 11
3% more funds holding
Funds holding: 96 → 99 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.14% less ownership
Funds ownership: 14.37% → 14.23% (-0.14%)
3% less capital invested
Capital invested by funds: $110M → $107M (-$3.33M)
38% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Atria Investments
Charlotte,
North Carolina
|
+$2.87M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$1.54M |
| 3 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$1.47M |
| 4 |
FSA
Financial Sense Advisors
San Diego,
California
|
+$1.31M |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$6.05M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.74M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$2.66M |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$1.38M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.26M |
PJP Hedge Fund Activity: Q2 2017 in Review
99 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Invesco Pharmaceuticals ETF (PJP) for Q2 2017, worth a combined $107M — down 3% from $110M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new PJP positions and 11 closed out — a net gain of 3 holders — while 21 added to existing stakes and 34 trimmed.
The largest buyer was Atria Investments, opening a new position worth an estimated $2.87M. The largest seller was Bank of America, cutting an estimated $6.05M.
- 99 institutional investors held Invesco Pharmaceuticals ETF (PJP) as of Q2 2017, up from 96 in Q1 2017.
- Funds reported $107M of Invesco Pharmaceuticals ETF stock for Q2 2017, down 3% quarter-over-quarter.
- 14 funds opened new Invesco Pharmaceuticals ETF positions in Q2 2017 and 11 closed out, a net change of +3 holders.
- The largest Invesco Pharmaceuticals ETF buyer in Q2 2017 was Atria Investments, an estimated $2.87M added.
- The largest Invesco Pharmaceuticals ETF seller in Q2 2017 was Bank of America, an estimated $6.05M sold.
Based on aggregated 13F filings for Q2 2017.